Liraglutide's Impact on Postprandial Lipoprotein Kinetics, Liver Fat, and De Novo Lipogenesis Explored in T2DM Trial

Type 2 diabetes (T2DM) is characterized by insulin resistance and impaired glucose metabolism, often accompanied by dyslipidemia and increased hepatic fat accumulation. These metabolic disturbances contribute to cardiovascular disease risk, a major complication of T2DM. Current treatments often focus on glycemic control but may not fully address the complex interplay of lipoprotein metabolism and liver fat. GLP-1 receptor agonists like Liraglutide are known for their glucose-lowering effects and weight loss benefits, but their specific impact on postprandial lipid handling, particularly chylomicron and VLDL kinetics, and hepatic de novo lipogenesis (DNL) in T2DM patients remains an area of active investigation. Understanding these mechanisms could reveal new therapeutic avenues for managing dyslipidemia and fatty liver in T2DM.

This single-center, randomized, single-blind, placebo-controlled Phase 4 study enrolled 23 participants with type 2 diabetes. Participants were randomized to receive either Liraglutide or placebo via subcutaneous injection once daily for a total of 3.5 months. The Liraglutide arm followed a dose escalation: 0.6 mg daily for one week, then 1.2 mg daily for one week, and finally 1.8 mg daily for the remaining 3.5 months. The primary aim was to evaluate the effect of Liraglutide on postprandial chylomicron and VLDL kinetics, liver fat content, and hepatic de novo lipogenesis.

The provided trial registration document outlines the study's design and objectives but does not include any specific results or findings from the completed trial. Therefore, no quantitative data, statistical significances, or mechanistic insights can be reported from this source. The study aimed to evaluate Liraglutide's impact on postprandial chylomicron and VLDL kinetics, liver fat, and hepatic de novo lipogenesis in individuals with type 2 diabetes. Without the published results, the outcomes of these investigations remain unknown.